Cargando…
Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary
INTRODUCTION: Approval of the anti‐amyloid monoclonal antibodies has stimulated an important discussion of the value to be placed on the magnitude of slowing achieved by treatment compared to placebo. METHODS: The minimal clinically important difference (MCID) was reviewed in the context of other me...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372384/ https://www.ncbi.nlm.nih.gov/pubmed/37521521 http://dx.doi.org/10.1002/trc2.12411 |